Newsletter | July 27, 2020

07.27.20 -- The Expanding Role Of Artificial Intelligence In Clinical Research

Featured Editorial
Industry Insights
Trial Design In The Time Of COVID-19: Complex And Efficient

Are platform and adaptive trials the same? How can they improve research in the time of COVID-19? This blog post answers these questions and reflects on their features and benefits.

How Thoughtful, Strategic Design Improves The Patient Experience In Clinical Trials

A technology or solution created with thoughtful, strategic design will elevate the experience of the user. By applying the strength and worldwide reputation of IBM design to clinical trial technology, the company is set to revolutionize — and significantly improve — the experiences of both patients and site personnel.

"Validation" Or "Qualification": What’s The Difference?

What is the difference between qualification and validation? This question comes up frequently with both internal and external clients. 

21 CFR Part 11 Compliance For Clinical Research Sites

Understanding and following the detailed regulations around 21 CFR Part 11 requires a significant amount of time, resources, and knowledge. We’re here to pass along to you as much of this information as possible so you can navigate with ease everything required for compliance — including validation, training, and process development.

An Excerpt From CRO Quality Benchmarking: Phase 2/3 Service Providers, 12th Edition

Which provider is best to conduct a given trial? Who will perform the best? This report includes insights from 233 experienced Phase 2/3 outsourcers and nearly 700 service provider encounters — all helping to frame what you need to be in the driver’s seat.

Accelerating Clinical Trials: The New And Future Normal

Keeping clinical trials operating efficiently during the COVID-19 pandemic is forcing the life sciences industry to adopt new working practices. Supporting these with the right collaborative technologies will help ensure a long-term and positive impact on streamlining clinical trial setup, execution, and results.

DIA Keynote Calls For Expanded COVID-19 Trial Parameters

Cancer survivor Mary Elizabeth Williams explores the clinical trial process for the patient population most directly impacted by the COVID-19 virus.

Accelerate More Molecules To Clinic

As the nature of the target molecule becomes increasingly challenging, the need is to move away from the current linear and siloed drug development approach.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.